| |
|
|
|
|
|
|
|||
|
Blood, 15 July 2008, Vol. 112, No. 2, pp. 256-263. Prepublished online as a Blood First Edition Paper on March 17, 2008; DOI 10.1182/blood-2007-10-118497.
Submitted October 18, 2007
Neuroinflammation Research Center, Department of Neuroscience, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States * Corresponding author; email: ransohr{at}ccf.org.
In vitro studies have implicated chemokine receptors in consumption and clearance of specific ligands. We studied the role that various signaling chemokine receptors play during ligand homeostasis in vivo. We examined the levels of ligands in serum and CNS tissue in mice lacking chemokine receptors. Compared to receptor-sufficient controls, Cx3cr1-/- mice exhibited augmented levels of CX3CL1 both in serum and brain, and circulating levels of CXCL1 and CXCL2 were increased in Cxcr2-/- mice. CCR2-deficient mice showed significantly increased amounts of circulating CCL2 when compared to wild type mice. Cxcr3-/- mice revealed increased levels of circulating and brain CXCL10 after EAE induction. CCR2-deficient peripheral blood and resident peritoneal cells exhibited reduced binding capacity and biological responses to the CCR1 ligand CCL3, suggesting that elevated levels of CCR2 ligands had down-regulated CCR1. The results indicate that signaling chemokine receptors clear chemokines from circulation and tissues. These homeostatic functions of signaling chemokine receptors need to be integrated into safety and efficacy calculations when considering therapeutic receptor blockade.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||